Chimeric antigen receptor-T cell therapies: The changing landscape

eJHaem

article

Salyka M. Sengsayadeth¹  Bhagirathbhai R. Dholaria¹  Bipin N. Savani¹  Olalekan O. Oluwole¹ 

[1] Section of Hematology and Stem Cell Transplant, Vanderbilt Ingram Cancer Center, Department of Medicine, Vanderbilt University Medical Center;Veterans Affairs Medical Center, Tennessee Valley Healthcare System

关键词: chimeric antigen receptor;    leukemia;    multiple myeloma;    non-Hodgkin lymphoma;    T cell;   

DOI  :  10.1002/jha2.340

来源: Wiley

【 摘 要 】

Since the advent of the first Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR-T) cell therapy in 2017 foraggressive large B cell lymphoma, the excitement around this nascent,cutting-edge therapy has only continued to grow in the arena of Hematology and Oncology. CAR-T cell therapy involves harnessing a patient’sown or donor immune cells and subsequently engineering these T cellsto recognize specific antigens on tumor cells and in turn causing cancer cell death. The development of this new treatment modality hasbeen a beacon of the direction of where cancer treatment is headedin the future. Leaving behind the diffuse cytotoxic side effects of standard chemotherapy in its path, CAR-T cell therapy has become aneffective and well-tolerated therapeutic option for many patients withrelapsed or refractory hematologic malignancies. However, as experience with CAR-T cell therapy continues to develop and data regarding long-term efficacy and side effects mature, we are learning thatthere is more to learn. Herein this special issue, we discuss what weknow, what the current challenges are, and what we need to learn inthe future regarding this avant-garde therapy that has changed thelandscape for so many with life-threatening hematologic malignancies(Table 1).

【 授权许可】

Unknown